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Studies of the widespread use of complementary and alternative medicine (CAM) 
demonstrate that CAM users relate to both subjective, experience-based knowledge and 
medical knowledge in treatment decisions. The aim of this study was to explore lay and 
medical risk perceptions associated with CAM and conventional medicine.  
Patients and Methods 
Twenty-five Norwegian users of CAM who were diagnosed with cancer or multiple 
sclerosis and 12 of their doctors participated in in-depth interviews in an explorative, 
qualitative study.  
Results 
Rather fundamental differences in risk perceptions were revealed that influenced 
treatment decisions and risk communication in clinical encounters. While the CAM users 
considered conventional medicine as potentially risky and related this to experiences of 
severe adverse effects of conventional treatments, they perceived CAM as “natural” and 
“safe”.  Doctors‟ risk perceptions were quite the contrary, mainly because of lack of 
scientific evidence for CAM as safe and beneficial.  
Conclusion  
For the safety of CAM users, such divergent risk perceptions may have far reaching 
consequences. CAM users need to be met where they actually position themselves as 
decision–makers based on their approaches to experiences, knowledge, and science. An 
awareness of differing lay and medical risk perceptions associated with CAM and 
conventional medicine both in research, doctor-patient communication, and education of 




cancer; complementary and alternative medicine; decision making; doctor-patient 








From a biomedical perspective, risk is understood as the objective and evidence-based 
risk of an adverse outcome when performing any diagnostic or therapeutic procedure [1-
2]. Comprehensive research based on this approach to risk provides important knowledge 
on risks related to conventional treatments. Comparatively, little research has investigated   
patients‟ individual risk perceptions. This fact can be linked to the established scientific 
understanding of risk as an objective phenomenon. In recent risk research it has been 
argued that there exists a significant problem with using “objective” epidemiological risk 
assessment because risk is reduced to a statistical measure that does not take into account 
patients‟ attitudes or risk-taking behaviors [3]. A hermeneutic understanding of risk as a 
social construct including uncertainty and subjective elements has thus been introduced 
[3-7]. How risk is understood may have a significant influence on how it is handled, and 
experts and members of the public may disagree about existing risks because they 
understand risk differently and have different worldviews, experiences, and education [6-
10]. This argumentation may be especially relevant in approaching risks associated with 
patients‟ use of complementary and alternative medicine (CAM), as CAM use is often 
unregulated, based on lay knowledge, and initiated by patients themselves or by 
unauthorized CAM practitioners [7]. 
CAM and risk 
This study explored risk perceptions among a sample of Norwegian CAM users 
diagnosed with cancer or multiple sclerosis (MS) and their doctors. The Norwegian Act 
No. 64 of 27 June 2003 [11] defines CAM as  
 
(…) health related treatment which is practiced outside the established health 
services and which is not practiced by authorized health personnel. Treatment 
performed inside the health service or by health personnel is included by the 
concept alternative medicine when methods that normally are practiced outside 
the health service are used.  
 
Approximately 50 % of Norwegian cancer and MS patients use CAM [12-13]. Despite 





and a need for more research that enables patients to make informed treatment decisions 
has been emphasized by several authors [14-24]. The existing literature shows that 
benefits and low risk are associated with some specific CAM treatments used by MS and 
cancer patients when implemented properly [e.g., 14-16, 19, 25-27], while other 
treatments are considered unsafe or ineffective [e.g., 14-16, 18]. In general, CAM use has 
been interpreted as a result of both a positive attitude toward CAM and a somewhat 
negative attitude toward conventional health care. From the patient perspective, 
encounters between patients and CAM can produce benefits that induce new health 
practices [14-17, 19, 28-30].  Patients‟ negative attitudes toward conventional medicine 
can be linked to adverse effects of treatments, lack of conventional treatment options, or a 
lack of trust in conventional care [17-19, 24, 28-30].  CAM users seem to base their 
treatment decisions on lay constructions of a therapeutic pluralism that includes both 
scientific, medical knowledge and embodied and experience-based knowledge [7, 17, 28-
30]. Thus, there may be unexplored gaps between CAM users‟ and doctors‟ perceptions 
of risk. Such possible differences represent an important and under-investigated aspect of 
decision-making, communication, and patient safety in contemporary health care.  
Aims, risk definition and research questions 
The purpose of this study was to explore doctors‟ and cancer and MS patients‟ 
perceptions of risks associated with the use of CAM and conventional medicine based on 
an approach able to capture different stakeholders‟ risk experiences and understandings. 
The study was based on a sociocultural understanding of risk as a situation or event 
where something of human value is at stake, and where there is uncertainty about the 
potential for and realization of unwanted, negative consequences of the event. The 
research questions addressed were: 
1. How do CAM users diagnosed with cancer or MS perceive risks associated with 
conventional medicine and CAM? 
2. How do doctors perceive such risks? 
3. Are there differences in patients‟ and doctors‟ risk perceptions? If so, how can these 
differences be interpreted?  
The study is part of a larger qualitative study of cancer and MS patients‟ position 






Participants were selected via the Registry of Exceptional Courses of Disease (hereafter 
“the Registry”), which includes Scandinavian self-reported positive and negative courses 
of disease related to the use of CAM [31-32]. In this study, patients with cancer or MS 
were included because both patient groups are large, and their use of CAM is widespread 
and considered as potentially risky [12-13, 20-24]. Exceptional cases are deviant cases 
that can illustrate unusual and typical aspects of a phenomenon and be perceived as 
illuminative and information-rich [33-35]. The Registry contains information on patients 
representing different commitment to CAM and various experiences from the use of 
CAM and conventional medicine. It also contains medical records and contact 
information for the patients‟ doctors and CAM practitioners [31, 35]. Such a sample of 
CAM users and health care providers is time-consuming and challenging to establish, and 
the Registry can represent a rather unique possibility for idiographic sampling [36] for 
qualitative studies on different aspects of CAM as viewed from different stakeholders‟ 
perspectives. 
Patients  
As of December 31, 2008, 52 cancer patients (41 women, 11 men) and 58 MS patients 
(39 women, 19 men) were registered. Based on a document analysis of the Registry 
material on these 110 cases (a questionnaire, medical records, etc.), possible participants 
were selected. Specific differences with respect to gender or country were not identified. 
13 Norwegian cancer patients (12 women, 1 man) and 12 Norwegian MS patients (9 
women, 3 men) were included. Inclusion continued until only a small amount of new 
information was obtained during interviews, and redundancy occurred. The data was then 
deemed to be saturated [37].   
The cancer patients ranged in age from 38 to 84. Seven had a higher education. The mean 
time since diagnosis was 9.2 years. The diagnoses were breast cancer (7), Hodgkin‟s 
lymphoma (2), prostate cancer (1), and ovarian cancer (1). The last two patients had rare 
cancer diagnoses that are not listed to avoid identification. Nutritional therapy, spiritual 
healing, and acupuncture were the CAM modalities most frequently used. Six used 





trajectory, while six discontinued or refused conventional cancer treatment at some stage 
after surgery. One patient refused all conventional treatment. 
The MS patients ranged in age from 39 to 55. Ten had a higher education. The number of 
years since being diagnosed with MS varied from 6 to 21. The distribution of MS 
subtypes [38] was: relapsing remitting (3), secondary progressive (6), and primary 
progressive (3). Acupuncture, nutritional therapy, homeopathy, and spiritual healing were 
the CAM modalities most frequently used. Three used alternative treatments exclusively. 
Doctors 
In 2009-2010, 15 doctors (five oncologists, five neurologists, and five general 
practitioners) who had treated 19 of the 25 patients in the study were invited to 
participate. All but one oncologist and two neurologists accepted. All participants (6 
women, 6 men) had a Western medical education. They ranged in age between 41 and 65, 
and worked within the Norwegian conventional health care system where they had been 




Qualitative interviews were the primary source of information, understood as being 
interactional, reciprocal, and reflexive processes [39], and directed toward understanding 
the participants‟ perspectives of their experiences, perceptions, or situations [40]. The 
patient interviews focused on personal history, experiences from conventional care, and 
reasons for and experiences from the use of CAM. They were performed face-to-face by 
the author and a research assistant, lasted 90-150 minutes, and took place in the patients‟ 
homes or at another meeting place chosen by the participant. The doctors were 
interviewed with the aim of gaining an understanding of their perspectives in general, and 
not regarding their experiences with patients in the study in particular. The main themes 
were experiences with patients‟ CAM use, risk perceptions associated with conventional 
medicine and CAM, and doctor-patient communication. Six were interviewed in their 
offices, one in his home, and five by telephone. These interviews lasted between 45 and 
90 minutes. All 37 interviews were audio-recorded and transcribed verbatim by a 






Qualitative content analysis and the systematic classification process of coding and 
identifying different themes or patterns were used to interpret the data [41]. The patient 
interviews were intensively read to gain a general understanding of main issues under 
investigation. They were then re-read and coded in NVivo 8 qualitative software, starting 
with line-by-line coding of ideas, themes, and concepts, and then developing secondary 
substantive codes that summarized key concepts across the data [41]. “Patients‟ and 
doctors‟ differing risk perceptions” was identified as an important empirical pattern in the 
patient material. The same procedure as described for the patient interviews was followed 
when analyzing the interviews with doctors. “Differences in risk perceptions” was 
highlighted by the participants also in these interviews. 
Ethical considerations 
The study was conducted according to the rules of the Helsinki Declaration [42]. The 
Regional Committee for Medical and Health Research Ethics and the Norwegian Data 
Protection Authority approved the Registry and the research project. The patients gave 
written consent to participate. The transcriptionist signed a written consent to 
professional confidentiality. The interviews were conducted with sensitivity to the needs 
and abilities of each participant [43].  
RESULTS 
Patients’ risk perceptions 
The patients differed in diagnosis, but their perceptions of risk were in general very 
similar. One difference was that while the cancer patients had been offered a regime of 
conventional treatments, some of the MS patients had been offered very limited 
conventional options. The patients had made great efforts to create a knowledge basis for 
their treatment decisions by reading medical and CAM literature as well as talking to 
doctors, CAM practitioners, and persons in their social networks about treatment options 
and experiences. 
Conventional treatment was perceived as a considerable health risk by many patients in 
both disease groups. For the cancer patients, this was often based on their experiences of 
dramatic, fatal cancer courses and substandard medical care in their families. They 





and “the treatment entailed so much suffering to no avail.” Several MS patients had 
themselves experienced severe adverse effects from conventional treatments like β-
interferon and cortisone before they decided to use CAM. Conventional treatments were 
also perceived as potential health risks based on what they had learned from their doctors 
about adverse effects. They often found it difficult to understand their “personal risk” 
based on risk statistics presented in clinical encounters. They described personal cost-
benefit assessments with regard to conventional treatment and risk. A cancer patient 
stated, “After reading up on what radiation does to the body, and looking at all the 
adverse effects versus the benefits when it comes to my diagnosis, I chose to decline.”   
Some patients were experienced conventional health care providers themselves. They 
used their professional knowledge combined with knowledge about CAM when they 
made their risk assessments and treatment decisions. A nurse who had cancer and 
declined all conventional treatment explained: 
 
I had faith that there are many roads to Rome. Most people having had similar 
operations experience severe adverse effects. I did not want to poison the body 
with chemotherapy and radiation. I had good reason [based on knowledge of 
conventional and alternative treatment options] to believe that I could reach a 
better goal without the conventional treatment that was offered, and I have 
reached that goal. 
 
How the patients perceived risks associated with conventional medicine and their 
experiences from risk communication with doctors strongly influenced their decision to 
use CAM. Most of them combined conventional and alternative treatment and often used 
CAM to strengthen their ability to benefit from conventional treatment. Many expressed 
that the goals of their CAM use were to cope and live better with their disease. In general, 
they described CAM as “safe”, “natural”, and “without adverse effects”.  None described 
negative effects of CAM use experienced by themselves or their significant others. From 
the media, they knew about patients who had negative experiences with CAM 
practitioners, CAM products, and the economic burden of using CAM. They did not 





practitioners they themselves had chosen were trustworthy. Many patients stated that they 
“owed themselves” to try out alternatives to conventional treatment because, as explained 
by a cancer patient, “at least, it wouldn‟t hurt me to try, whereas not to try could turn out 
as a really bad decision when I wanted to live a good life with my cancer and maybe even 
could get cured”. CAM therapies were often evaluated based on bodily experiences, as a 
kind of “bodily risk assessment”. CAM represented something “positive” and “harmless” 
the patients themselves could do to strengthen their health by taking active part in 
treatment decisions and healing processes.  
Doctors’ risk perceptions 
The doctors were specialized into different fields of medicine, two of them also in CAM. 
Despite their different competences, they had a common understanding of risk as the 
evidence-based risk of an adverse outcome connected to specific treatments and 
diagnoses. Oncologists had more concerns about CAM and risk than neurologists and 
general practitioners, based on negative consequences of patients‟ CAM use observed in 
their oncological practice. Those who were also trained in CAM meant that far the most 
CAM treatments are “safe” and “beneficial”. They were very aware, however, that some 
CAM treatments and unauthorized CAM practitioners could represent risk to patients, 
and they had been confronted about the safety of CAM by other doctors who they meant 
needed more education about CAM and safety to become more open-minded. 
The doctors had been trained to relate to statistical risk numbers revealed in biomedical 
studies in their assessments of clinical treatment options. In general, they perceived 
conventional medicine to be quality-assured, despite possible adverse effects:  
 
One benefit of working with these cancer patients [patients with lymphoma] is that 
we know from cancer statistics and clinical trials that their chances to get well if 
they use [certain conventional cancer treatments] are very good … Of course, this 
motivates us as doctors to try to motivate our patients to keep up with the possible 
adverse effects of the treatments. 
 
The doctors found clinical studies of preparations and treatment regimens to be crucial 






The problem with so many of these CAM preparations is that I don‟t know what 
they contain … What we have tried to do [in two cases where the oncologist 
thought that interaction between a conventional and a CAM treatment caused the 
death of the patient] was to notify The Norwegian Pharmacovigilance Advisory 
Board but they didn‟t want to hear about it because it [the CAM treatment] wasn‟t 
registered as a drug. 
 
Some CAM therapies, e.g., acupuncture, were perceived as uncomplicated, whereas e.g., 
cancer patients‟ use of St. John‟s Wort and certain unconventional clinics were perceived 
as risky behavior. Several doctors had observed interventions between conventional 
treatments and CAM products: “I have also seen several patients who have died – 
probably because they have combined our treatment with other drugs, or only taken other 
preparations. So it‟s – it's scary.”  
The doctors described their risk assessments and risk communication in clinical 
encounters as heavily influenced by the acuteness and prognoses of the patients‟ disease. 
CAM use was not that problematic if the prognoses were positive or if there was no 
conventional treatment available. The oncologists had experienced dramatic 
consequences of delay or denial of conventional treatment in favor of CAM use in their 
practices: 
 
It turns out that the consequences of embracing one of those new age – a new 
outlook on life, in a way, maybe call it a philosophy of life that makes you believe 
that the soul can heal almost anything, then you remove yourself really far from ... 
our kind of medicine. And then it ends up that a lot of them ... don‟t accept 
[conventional] treatment. … Of course, that is the major concern. 
 
Delay or denial of essential conventional cancer or MS treatment was perceived as the 
overall risk associated with patients‟ use of CAM. The doctors said they felt frustrated 
and uncertain when seriously ill patients did not trust medical knowledge and chose to 





not only physically, but also psychologically and economically. The oncologists in 
particular found it difficult that they sometimes had no choice but to accept what they 
perceived as risky behavior. One said: “Patients suffer in the name of freedom ... these 
are grown-ups, you know – in their right mind, and ... then they have the full right to 
decide their treatment themselves.” 
All the doctors expressed the need for scientific risk evaluations of specific CAM 
therapies. They also meant that more knowledge about risk communication with users of 
CAM would be very useful in clinical practice, as they had experiences from situations 
where patients did not seem able to relate to medical information and medical risk 
perspectives. 
DISCUSSION 
The analysis revealed rather fundamental differences between patients‟ and doctors‟ 
perceived risks, and considerable challenges in risk communication. The patients often 
perceived potential adverse effects related to the use of conventional medicine as health 
risks and CAM therapies and products as being generally safe. The doctors perceived 
conventional treatments as quality-assured through scientific studies and thereby safe, 
whereas many CAM treatments were perceived as possibly harmful. This discussion will 
focus on how such differences in lay and medical risk perceptions can be understood, and 
their possible implications.  
Based on a sociocultural understanding of risk, perceptions of risk can be considered as 
fundamental to the way both lay people and experts organize their social world [2-8, 17]. 
The empirical patterns revealed in this study suggest that contextual factors, scientific 
knowledge, individual knowledge and experience, as well as instinctive reactions in 
stressful situations seem to have explanatory power in understanding different 
stakeholders‟ risk perceptions and risk behavior. Many of the CAM users‟ risk 
perceptions, e.g., their assessments of conventional treatments as holding considerable 
health risks based on knowledge of the suffering of significant others, can be interpreted 
as examples of subjective, lay constructions of risk. The doctors‟ perceptions are 
examples of “objective”, scientific risk knowledge. The encounter between patients‟ and 
doctors‟ risk perceptions when these are conflicting can be perceived as “risk as politics”, 





Particularly in stressful situations, lay people seem to look to their positive and negative 
feelings as a guide to their evaluation of an activity‟s risks and benefits [44-46]. People 
need to understand their personal risk, while they experience that doctors often approach 
risk very analytically and logically, and reality is encoded in abstract symbols, words, and 
numbers [2-9, 44-46]. In this study, patients‟ risk assessments were based on their own 
and significant others‟ experiences from suffering in conventional health care as well as 
to which extent the patients perceived a treatment, whether it was conventional and 
scientifically evaluated or not, as a potential threat to their health and well-being. 
Perceived risk, trust, and uncertainty were closely connected in these patients‟ risk 
behavior. Cure is often perceived as the main treatment goal by doctors, but several 
patients perceived coping and well-being in their living with MS or cancer as their most 
realistic and important treatment goals, and found CAM very useful to reach them. Peters 
and colleagues describe four kinds of uncertainty that may exist in health care settings 
and result in patient strategies such as those revealed in this study: uncertainty about the 
magnitude or severity of possible benefits and risks, the strength of current evidence, how 
to weigh risks and benefits, and about the likelihood of different outcomes [9].  
The use of CAM as a lay health practice can be linked to the politicization of health – 
returning control of one‟s health to the individual and control of the health system to the 
community. The flexible use of various sources of knowledge can afford modern health 
care users considerable latitude in accepting or rejecting forms of evidence as 
authoritative and trustworthy [3, 9, 44-47]. Prior [47] points out that lay people are 
experts by virtue of having experience, but that “experience on its own is rarely sufficient 
to understand the technical complexities of disease causation, its consequences and its 
management” [47, p. 53]. Improved patient understanding of actual risk of recurrence or 
death is required in order for patients to be able to make more informed treatment 
decisions [9-10, 16, 23-24]. However, although patients in clinical encounters often are 
expected to understand consequences of treatment decisions being quantified by 
statistical numbers, they are in many situations not able to or willing to do so [4-5, 44, 
46]. Doctors, on their side, often do not take into account the attitudes of patients‟ risk-





This analysis leaves us with a key question: How can we handle differences in lay and 
medical understandings of risk, i.e., when “our ancient instincts and our modern scientific 
analyses clash” [44, p. 21], and consequently, patient safety may be threatened? Based on 
the results of this study, it seems to be essential to take into consideration in risk research, 
risk communication, and risk education that risk actually often is perceived differently by 
patients who are users of CAM and their doctors. The basis for CAM users‟ decision-
making, including their risk assessments, is often a complex construct of scientific and 
experience-based knowledge. This is important information that should be acknowledged 
in clinical encounters. 
Methodological aspects  
The participants were recruited via the Registry of Exceptional Courses of Disease. The 
patients had reported “exceptionally positive” courses of cancer and MS related to their 
use of CAM. No “exceptionally negative” courses of MS and cancer have so far been 
reported to the Registry. It is likely that patients with negative experiences from the use 
of CAM will perceive CAM as a health risk, as is the case with negative reports from 
patients with other diagnoses in the Registry [48-49]. Most studies report positive user 
experiences from the widespread use of CAM, however [e.g., 13, 17, 19, 28-30], and 
these CAM users need available and quality-assured risk information. 
Tendencies to verify preconceived interpretations of patients‟ and doctors‟ risk 
perceptions were expressed and processed [39] through working with a co-researcher 
from the larger, qualitative study [28-30] and two patients and one doctor who 
participated. To assess the quality of qualitative studies, we may ask whether the 
credibility of our claims is supported by sufficient evidence [50]. It is not possible to 
claim that the results of this study can be generalized to populations of cancer or MS 
patients or transferred to other diagnostic groups. However, this study, as well as other 
studies on health consumers‟ lay theories, indicate that lay theories are important factors 
in patients‟ decision–making processes [7, 17, 28-30, 45-47] and should be taken into 
account in both in-depth studies and large-sample, attitude-based surveys of risks 






This study revealed rather fundamental gaps in risk perceptions associated with the use of 
conventional medicine and CAM among MS and cancer patients and their doctors. These 
differences strongly influenced risk communication and patients‟ decision-making. While 
the patients perceived conventional medicine as potentially risky and CAM as safe, their 
doctors‟ perceptions were quite the contrary. CAM use tends to be widespread among 
MS and cancer patients and in Western populations in general, and divergent risk 
understandings may have far reaching consequences for CAM users‟ decision-making 
and risk communication in clinical encounters. CAM users need to be met where they 
actually position themselves as decision–makers based on their approaches to 
experiences, knowledge, and science. Thus, in clinical education and practice, there 
should be a greater focus on differing risk perceptions and their possible implications for 
doctor-patient communication and patients‟ decision-making to strengthen patient safety 
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